Literature DB >> 578850

Reversal of central anticholinergic syndrome by galanthamine.

A Baraka, S Harik.   

Abstract

Ten volunteers were given 2 mg scopolamine intravenously (IV) to produce substantial drowsiness and sleepiness. Galanthamine, 0.5 mg/kg IV, effectively reversed the central anticholinergic syndrome produced by scopolamine. Electroencephalographic monitoring of two subjects matched the observed changes of consciousness: scopolamine replaced the dominant awake alpha rhythm with a disorganized, slow, 4- to 6-Hz activity. Galanthamine promptly returned to EEG pattern to the control, awake state. Galanthamine produces effective, safe, and long-lasting reversal of the central anticholinergic syndrome in man.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 578850

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  11 in total

1.  Reversal of mecamylamine-induced effects in healthy subjects by nicotine receptor agonists: Cognitive and (electro) physiological responses.

Authors:  Ricardo Alvarez-Jimenez; Ellen P Hart; Samantha Prins; Marieke de Kam; Joop M A van Gerven; Adam F Cohen; Geert Jan Groeneveld
Journal:  Br J Clin Pharmacol       Date:  2018-02-20       Impact factor: 4.335

2.  Galantamine reverses scopolamine-induced behavioral alterations in Dugesia tigrina.

Authors:  Latha Ramakrishnan; Christina Amatya; Cassie J DeSaer; Zachary Dalhoff; Michael R Eggerichs
Journal:  Invert Neurosci       Date:  2014-01-09

3.  Effects of different doses of galanthamine, a long-acting acetylcholinesterase inhibitor, on memory in mice.

Authors:  J E Sweeney; E S Bachman; J T Coyle
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 4.  Clinical pharmacokinetics of galantamine.

Authors:  Martin R Farlow
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 5.  Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.

Authors:  David G Wilkinson; Paul T Francis; Elias Schwam; Jennifer Payne-Parrish
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

6.  Antagonistic activity of galanthamine on constant infusion of pancuronium in rats.

Authors:  D A Cozanitis; F van de Pol; H van Wezel; J F Crul
Journal:  Experientia       Date:  1981-12-15

7.  Effects of four non-cholinergic cognitive enhancers in comparison with tacrine and galanthamine on scopolamine-induced amnesia in rats.

Authors:  P Chopin; M Briley
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 8.  Mini Review: Anticholinergic Activity as a Behavioral Pathology of Lewy Body Disease and Proposal of the Concept of "Anticholinergic Spectrum Disorders".

Authors:  Koji Hori; Kimiko Konishi; Misa Hosoi; Hiroi Tomioka; Masayuki Tani; Yuka Kitajima; Mitsugu Hachisu
Journal:  Parkinsons Dis       Date:  2016-09-22

Review 9.  The case of galantamine: repurposing and late blooming of a cholinergic drug.

Authors:  Hermann Am Mucke
Journal:  Future Sci OA       Date:  2015-09-03

10.  EEG machine learning for accurate detection of cholinergic intervention and Alzheimer's disease.

Authors:  Sonja Simpraga; Ricardo Alvarez-Jimenez; Huibert D Mansvelder; Joop M A van Gerven; Geert Jan Groeneveld; Simon-Shlomo Poil; Klaus Linkenkaer-Hansen
Journal:  Sci Rep       Date:  2017-07-18       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.